PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

06 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

21 May 2024 18:50:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

07 May 2024 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

06 May 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

01 May 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

02 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

27 Mar 2024 10:23:38 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

12 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

27 Feb 2024 16:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

26 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

07 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

04 Feb 2024 15:29:07 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

13 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

09 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

08 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

06 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

31 Oct 2023 16:03:07 By Nasdaq GlobeNewswire

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

19 Oct 2023 08:00:00 By Nasdaq GlobeNewswire